Status:
UNKNOWN
Role of ABUS as an Alternative to Breast MRI in Assessing Response to Neoadjuvant Chemotherapy
Lead Sponsor:
The Leeds Teaching Hospitals NHS Trust
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-100 years
Phase:
NA
Brief Summary
Some women who have been diagnosed with a breast cancer will require chemotherapy as part of their treatment. The chemotherapy can be given before breast surgery - neoadjuvant chemotherapy or after br...
Eligibility Criteria
Inclusion
- All female participants eligible for neoadjuvant chemotherapy and planning surgical treatment
- Able to give informed consent
Exclusion
- All female particpants having neoadjuvant chemotherapy as palliative treatment with no surgery planned
- Unable to provide informed consent
- Unable to have breast MRI scan due to clautrophobia or allergy to gadolineum
Key Trial Info
Start Date :
August 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04468867
Start Date
August 22 2019
End Date
June 30 2022
Last Update
July 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leeds Teaching Hospitals NHS Trust
Leeds, West Yorkshire, United Kingdom, LS9 7TF